Management of Psychotropic Medicines’ Side Effects: Recognition, Monitoring and Emergency Care

Psychotropic medicines can restore sleep, mood, thought and function, but every medicine has a risk–benefit balance. Managing side effects means asking about them proactively, measuring what can be measured, distinguishing a benign effect from a medical emergency, explaining options without blame, and changing treatment safely rather than abandoning an effective medicine unnecessarily.

Learning objectives

• Classify adverse effects by time of onset, mechanism, severity and reversibility.
• Recognise common and life-threatening reactions to antidepressants, antipsychotics, mood stabilisers, benzodiazepines and ECT.
• Use baseline and follow-up monitoring to detect metabolic, cardiovascular, neurological, haematological, hepatic, renal and endocrine toxicity.
• Apply practical first responses to acute dystonia, akathisia, parkinsonism, tardive dyskinesia, serotonin syndrome, neuroleptic malignant syndrome, lithium toxicity and severe drug rashes.
• Communicate risk, document an adverse drug reaction and report it through local pharmacovigilance systems.

1. A safe response to any suspected side effect

1. Stabilise. Use ABCDE, vital signs, capillary glucose, oxygen saturation and level of consciousness. Call for help early if unstable.
2. Describe the event. Onset, dose and recent changes, timing after each dose, progression, associated symptoms, exposure to other medicines/substances, allergies and previous reactions.
3. Check the medicine list. Include prescriptions, over-the-counter analgesics, antihistamines, herbal products, alcohol, recreational drugs and recently stopped medicines.
4. Decide urgency. Is this expected and tolerable, clinically important but stable, or a life-threatening syndrome?
5. Investigate selectively. ECG, glucose, electrolytes, renal/liver function, full blood count, CK, drug levels, pregnancy test, toxicology or imaging according to the suspected reaction.
6. Modify safely. Reduce, withhold, switch or continue only after considering withdrawal, relapse and the severity of the reaction. Abruptly stopping some medicines creates its own emergency.
7. Explain and record. Tell the patient what happened, what to avoid, the warning symptoms, the follow-up date and who is responsible. Add a clear adverse-reaction entry to the record.

2. Classifying adverse effects

3. Antidepressant adverse effects

3.1 Common SSRI and SNRI effects

• Gastrointestinal: nausea, loose stool and appetite change often improve during the first weeks. Take with food if appropriate and reassess persistent weight loss or dehydration.
• Sleep and activation: morning dosing may reduce insomnia; night dosing may suit sedation. New agitation, impulsivity, reduced need for sleep or suicidal thinking needs urgent review for activation, bipolarity or akathisia.
• Sexual dysfunction: reduced libido, delayed orgasm or erectile difficulty can persist. Ask routinely, consider dose/timing changes or a carefully chosen alternative rather than leaving the patient to stop suddenly.
• Hyponatraemia: suspect new confusion, headache, nausea, seizures or falls, especially in older adults, low body weight or those taking diuretics. Check sodium urgently.
• Bleeding: serotonin reuptake inhibition can increase gastrointestinal or bruising risk, especially with NSAIDs, aspirin, anticoagulants or antiplatelets.
• Blood pressure: monitor with SNRIs, particularly venlafaxine and duloxetine. Severe headache, chest pain or marked hypertension needs urgent assessment.

3.2 Serotonin syndrome

Serotonin syndrome usually follows a serotonergic combination, overdose or rapid dose escalation. Features include agitation, anxiety, diaphoresis, diarrhoea, tremor, hyperreflexia, inducible or spontaneous clonus, myoclonus, hyperthermia and rapidly changing mental state. Severe cases develop rigidity, seizures, rhabdomyolysis, renal failure and shock.

1. Stop serotonergic agents and seek urgent medical/toxicology advice.
2. Assess airway, breathing, circulation, temperature, glucose, renal function, electrolytes and CK; treat hyperthermia and complications.
3. Use a quiet environment and supervised benzodiazepine treatment according to local emergency protocol; avoid physical struggling and unnecessary stimulation.
4. Do not confuse serotonin syndrome with NMS, anticholinergic toxicity, severe withdrawal, sepsis or stimulant toxicity. Clonus and hyperreflexia favour serotonin excess; lead-pipe rigidity and slower onset favour NMS.

3.3 Antidepressant withdrawal

Discontinuation symptoms may include dizziness, “electric shock” sensations, nausea, vivid dreams, irritability, anxiety, sweating, insomnia and flu-like feelings. They are more likely after abrupt cessation, short half-life medicines and long treatment. Distinguish withdrawal from relapse. Explain the plan before changing treatment and taper gradually, often over weeks or longer depending on medicine and patient response.

4. Antipsychotic adverse effects

4.1 Extrapyramidal symptoms (EPS)

Example emergency dosing: local protocols may use procyclidine 5–10 mg IM/IV or benztropine 1–2 mg IM/IV for acute dystonia, with observation and repeat dosing only under trained clinical supervision. Check anticholinergic contraindications and local formulary; a laryngeal dystonia is an airway emergency.

4.2 Neuroleptic malignant syndrome (NMS)

Suspect NMS in a patient exposed to dopamine blockade or rapid dose change who develops fever, severe rigidity, altered consciousness, autonomic instability, tachycardia, sweating, dysphagia, incontinence and raised CK. It can occur with any antipsychotic, including atypicals, and after abrupt withdrawal of dopaminergic medicine.

• Stop the suspected medicine and obtain emergency medical/critical-care review.
• Assess airway and breathing; monitor ECG, temperature, urine output, renal function, electrolytes, CK, full blood count and liver function.
• Cool, hydrate and treat complications; manage rhabdomyolysis, renal failure, arrhythmia and thrombosis.
• Dantrolene, bromocriptine or other specialist interventions are reserved for appropriately supervised severe cases; do not self-administer or delay transfer while seeking a named antidote.
• After recovery, document the reaction clearly and plan any re-challenge with psychiatry and medical supervision.

4.3 Metabolic adverse effects

Weight gain, central adiposity, dyslipidaemia, insulin resistance, type 2 diabetes and fatty liver are especially associated with some antipsychotics. Preventive care includes baseline weight, waist, blood pressure, glucose/HbA1c and lipids; repeat measurements at early follow-up and regularly thereafter; dietary and physical-activity support; smoking cessation; and prompt treatment of diabetes or dyslipidaemia. Do not wait for severe obesity before discussing change.

4.4 Cardiovascular and autonomic effects

• QT prolongation: review syncope, palpitations, congenital long-QT, bradycardia, electrolyte abnormalities and interacting medicines. Obtain ECG when indicated and correct potassium/magnesium abnormalities.
• Orthostatic hypotension: check lying and standing blood pressure, hydration, falls risk and other alpha-blocking medicines. Rise slowly and review dose.
• Myocarditis/cardiomyopathy with clozapine: suspect chest pain, breathlessness, persistent tachycardia, fever, fatigue or unexplained hypotension early in treatment. Urgent ECG, troponin, inflammatory markers and echocardiography/specialist assessment may be required.
• Venous thromboembolism: consider risk in severe sedation, immobility, obesity and dehydration; investigate unilateral swelling, chest pain or sudden breathlessness urgently.

4.5 Prolactin and sexual/endocrine effects

Galactorrhoea, amenorrhoea, reduced libido, erectile dysfunction, infertility and breast discomfort may reflect hyperprolactinaemia. Ask rather than waiting for a spontaneous complaint. Check prolactin when symptoms or a high-risk medicine makes it clinically useful, exclude pregnancy and thyroid disease where relevant, and review dose or alternative treatment.

4.6 Clozapine-specific adverse effects

• Agranulocytosis: fever, sore throat, mouth ulcers or infection require an urgent full blood count and programme-specific action. Do not delay assessment.
• Constipation and ileus: ask about bowel movements at every review, prescribe prevention where appropriate, encourage fluids and activity, and urgently assess abdominal pain, distension, vomiting or absent stool/flatus.
• Seizures: risk rises with dose, rapid titration and interacting medicines; urgent review is required after a seizure.
• Hypersalivation and sedation: assess aspiration and night-time safety, review dose and interacting sedatives.
• Smoking changes: stopping or restarting tobacco smoke can alter clozapine concentration; notify the prescriber and monitor clinical status.

5. Mood stabiliser adverse effects

5.1 Lithium

Common effects include fine tremor, nausea, diarrhoea, thirst, polyuria, weight change and cognitive dulling. Long-term effects include hypothyroidism, hyperparathyroidism/hypercalcaemia, nephrogenic diabetes insipidus and chronic kidney disease.

• Red flags: coarse tremor, worsening vomiting/diarrhoea, ataxia, dysarthria, confusion, muscle weakness, hyperreflexia, seizures or reduced consciousness.
• What to check: exact dose and formulation, time of last dose and sample, hydration, salt intake, renal function, sodium, calcium, thyroid tests, interacting medicines and recent illness.
• Important interactions: NSAIDs, ACE inhibitors/ARBs, thiazide/loop diuretics, dehydration and abrupt changes in fluid or salt intake.
• Emergency treatment: urgent medical/toxicology assessment; do not induce vomiting or attempt home fluid loading. Severe cases may need haemodialysis based on level, symptoms and renal function.

5.2 Valproate

• Common effects: nausea, tremor, sedation, weight gain, hair changes and menstrual disturbance.
• Serious effects: hepatotoxicity, pancreatitis, thrombocytopenia and hyperammonaemic encephalopathy. Vomiting, abdominal pain, jaundice, easy bruising, profound drowsiness or new confusion need urgent tests.
• Monitor liver function and full blood count at baseline and according to local protocol. Follow current reproductive-safety restrictions; fetal malformation and neurodevelopmental risks are substantial.

5.3 Carbamazepine and lamotrigine

• Carbamazepine: dizziness, diplopia, ataxia, nausea, hyponatraemia, leukopenia, liver injury and serious skin reactions. Check sodium, full blood count and liver function when indicated; review enzyme induction and contraception/antiretroviral interactions.
• Lamotrigine: headache, nausea, dizziness and insomnia are common. A spreading rash, mucosal involvement, fever, facial oedema or systemic symptoms may signal Stevens–Johnson syndrome or toxic epidermal necrolysis; stop and seek urgent specialist assessment.

6. Benzodiazepine and sedative adverse effects

• Acute: drowsiness, slurred speech, ataxia, falls, impaired driving, confusion, paradoxical agitation and respiratory depression.
• Cumulative: tolerance, dependence, memory impairment, depression of breathing during sleep and increased falls or fractures.
• High-risk combinations: opioids, alcohol, sedating antihistamines, antipsychotics, gabapentinoids and other hypnotics.
• Overdose: assess airway and breathing; mixed overdose is more dangerous than isolated benzodiazepine exposure. Flumazenil is not routine and can precipitate seizures or withdrawal; involve toxicology/critical care.
• Withdrawal: taper according to duration, dose, medicine half-life and patient factors. Seizures, delirium, hallucinations and autonomic instability require medical admission.

7. ECT adverse effects

• Immediate: headache, nausea, jaw or muscle ache, transient confusion, agitation during recovery and short-term blood-pressure or pulse changes.
• Cognitive: anterograde learning difficulty and retrograde autobiographical memory loss; assess baseline cognition and ask about memory at every session.
• Anaesthetic/procedural: aspiration, arrhythmia, dental injury, prolonged seizure and rare status epilepticus; safety depends on anaesthetic assessment, airway equipment and monitoring.
• What to do: report persistent memory impairment, severe headache, chest symptoms, prolonged confusion, injury or seizure; review electrode placement, stimulus dose, treatment frequency and anaesthetic plan with the ECT team.

8. Monitoring schedule

9. Patient and family education

• Use plain language: “This medicine may cause sleepiness; do not drive or mix it with alcohol until we know how you respond.”
• Give a written list of emergency symptoms and a contact pathway.
• Ask the patient to show how they will take the medicine and explain what they will do if a dose is missed.
• Discuss pregnancy planning, breastfeeding and contraception without judgement. Never assume reproductive status.
• Explain that smoking, alcohol, herbal products and over-the-counter medicines can change drug levels or sedation.
• Invite a trusted supporter with consent, particularly where memory, psychosis, cognitive impairment or adherence is a concern.

10. Adverse-drug-reaction documentation

11. Emergency recognition table

12. Common mistakes

• Calling akathisia “worsening psychosis” and increasing the antipsychotic.
• Failing to ask about bowel movements in a patient taking clozapine or anticholinergic medicines.
• Prescribing a QT-prolonging combination without ECG or electrolyte review when risk factors exist.
• Stopping lithium, benzodiazepines or antipsychotics abruptly without a plan.
• Using anticholinergic treatment indefinitely for EPS without reviewing cognition, constipation and blurred vision.
• Missing antidepressant-induced mania because the patient originally presented with depression.
• Ignoring smoking cessation or restart when monitoring clozapine or olanzapine.
• Documenting “allergy” without describing the actual reaction, severity and date.

13. Worked cases

Case 1: Pacing after risperidone

A patient says, “I cannot keep still,” and walks continuously after a dose increase. Examine for tremor, rigidity and dystonia; ask about suicidal thoughts; review dose and other causes. Akathisia is likely. A dose reduction or switch and a supervised beta-blocker strategy may be safer than escalating treatment.

Case 2: Fever and rigidity

A patient on haloperidol develops fever, severe rigidity, tachycardia and confusion. Stop the suspected medicine, call emergency help, obtain CK/renal/electrolytes and manage as possible NMS. Do not wait for a psychiatric review or give more antipsychotic.

Case 3: Clozapine and constipation

A patient has not opened their bowels for five days and reports abdominal pain. Treat as possible gastrointestinal hypomotility or ileus. Urgent physical and surgical/medical assessment is required; do not simply add another sedative or tell the patient to wait.

14. Quick self-test

1. What are the first three priorities when a severe medicine reaction is suspected?
2. How can akathisia be distinguished from worsening agitation?
3. Name four red flags for NMS.
4. Which symptoms on clozapine require urgent blood count or medical review?
5. Why can abrupt benzodiazepine withdrawal be dangerous?
6. What tests are useful in suspected lithium toxicity?
7. Why should a patient with a severe rash on lamotrigine not be casually rechallenged?
8. What monitoring helps prevent antipsychotic metabolic harm?
9. What should be documented when an adverse reaction is entered in the record?
10. Why is a patient’s own report of sexual dysfunction clinically important?

Answers

1. Stabilise ABCDE/vital signs, identify the medicine and decide whether the event is an emergency requiring transfer.
2. Akathisia is an inner motor restlessness often linked to dose change; it is distressing, may resemble anxiety and can carry suicide risk. Examine and review timing rather than assuming relapse.
3. Fever, severe rigidity, altered consciousness, autonomic instability, dysphagia, raised CK and renal injury are examples.
4. Fever, sore throat, mouth ulcers, infection symptoms, severe constipation, abdominal pain, chest pain, breathlessness, palpitations, seizures or sudden severe sedation.
5. Dependence can produce seizures, delirium, severe autonomic symptoms and rebound anxiety or insomnia.
6. Correctly timed lithium level, renal function, electrolytes/sodium, hydration status, ECG where indicated and medication-interaction review.
7. It may represent Stevens–Johnson syndrome or toxic epidermal necrolysis, which can progress rapidly and recur more severely.
8. Weight/BMI, waist circumference, blood pressure, glucose/HbA1c, lipids, lifestyle review and medicine-specific risk assessment.
9. Drug/dose, timing, exact reaction, other exposures, examination and tests, action, outcome, alert and pharmacovigilance report.
10. It affects adherence, relationships, quality of life and informed choice; asking routinely reduces hidden discontinuation and distress.

References and further reading

• WHO. mhGAP guideline for mental, neurological and substance use disorders, 2023.
• NICE. Psychosis and schizophrenia in adults: prevention and management.
• NICE. Depression in adults: treatment and management.
• NICE. Bipolar disorder: assessment and management.
• NICE. Guidance on electroconvulsive therapy.
• Use current Uganda Clinical Guidelines, National Drug Authority safety alerts, local pharmacovigilance forms and hospital emergency protocols.